Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Sep 30:2020:5419707.
doi: 10.1155/2020/5419707. eCollection 2020.

KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature

Sarah Bouri  1   2 , Jean-Christophe Noël  1   2 , Xavier Catteau  1   2 , Walid Al Hajj Obeid  3 , Ilyas Svistakov  3 , Thierry Roumeguère  3 , Nicky D'Haene  1   2 , Sandrine Rorive  1   2
Affiliations
Case Reports

KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature

Sarah Bouri et al. Case Rep Urol. .

Abstract

Ovarian-like epithelial tumors of the testis, including serous borderline tumors, are rare entities. We report the case of a 60-year-old man with a left intratesticular mass who had a radical orchidectomy. Histologically, the tumor was identical to the ovarian counterpart showing a well-delineated cystic lesion characterized by intraluminal papillae. The papillae are lined by atypical cuboidal or ciliated cells and are associated with psammoma bodies. The tumor cells express cytokeratin 7 (CK7), cytokeratin 5-6 (CK5-6), cancer antigen 125 (CA125), estrogen (ER), progesterone (PR), Wilm's tumor gene (WT1), paired box gene 8 (PAX8), Ber-EP4, and epithelial membrane antigen (EMA). The diagnosis of a serous borderline tumor of the testis was proposed. Mutation testing using next-generation sequencing showed a Q61K KRAS gene mutation. To the best of our knowledge, this is the second case report of a serous borderline tumor of the testis with a Q61K KRAS gene mutation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest regarding the publication of this article.

Figures

Figure 1
Figure 1
Ultrasound features: heterogenous, hypoechogenic, and cystic tumor of 20 mm.
Figure 2
Figure 2
Macroscopically, the intratesticular tumor appeared cystic with an endoluminal solid area.
Figure 3
Figure 3
Microscopic view: cystic tumor with papillae lined by pseudo- or pluristratified atypical epithelium (hematoxylin and eosin) (×10).
See this image and copyright information in PMC

References

    1. Ibrahim A. S., Li C., al-Jafari M. S. Borderline serous papillary tumour of the testis: a case report and review of the literature. Anticancer Research. 2012;32(11):5011–5013. - PubMed
    1. Maruyama H., Ohyama N., Hosokawa Y., et al. Serous borderline tumor of the paratestis. Pathology International. 2008;58(5):311–316. doi: 10.1111/j.1440-1827.2008.02229.x. - DOI - PubMed
    1. Abdullah L. S., Gupta R., Arnst A. Intratesticular borderline serous tumor. International Journal of Urology. 2006;13(12):1536–1538. doi: 10.1111/j.1442-2042.2006.01575.x. - DOI - PubMed
    1. McClure R. F., Keeney G. L., Sebo T. J., Cheville J. C. Serous borderline tumor of the paratestis: a report of seven cases. The American Journal of Surgical Pathology. 2001;25(3):373–378. doi: 10.1097/00000478-200103000-00012. - DOI - PubMed
    1. Guarch R., Rivas A., Puras A., Pesce C. Papillary serous carcinoma of ovarian type of the testis with borderline differentiation. Histopathology. 2005;46(5):588–590. doi: 10.1111/j.1365-2559.2005.02017.x. - DOI - PubMed

Publication types